APAC expansion Summary: Precision for Medicine is actively expanding in Asia with new offices in Singapore and Japan in 2026, signaling a strategic opportunity to upsell integrated biomarker-driven services, local trial support, and Asia-Pacific regulatory navigation capabilities to regional and global sponsors accelerating trials in APAC.

Leadership depth Summary: Recent hires include a General Manager for Biospecimen Solutions, a General Manager for Labs Translational Sciences, and a VP of Clinical Development in Oncology, indicating a strengthened leadership and specialized execution capacity that can be aligned with sponsors needing enhanced biospecimen logistics, translational science, and oncology programs.

Biomarker focus Summary: Positioned as a biomarker-driven CRO with expertise spanning oncology and rare diseases, offering opportunities to engage sponsors seeking companion diagnostics, biomarker strategy, and centralized analytics to improve trial endpoints and adaptive design capabilities.

Global footprint Summary: With over 35 offices worldwide and 2000+ professionals, Precision for Medicine presents a scalable global delivery model that can handle multi-region trials, enabling conversations about global study execution, risk mitigation, and accelerated timelines for drug development programs.

Digital and data leverage Summary: The tech stack includes Alteryx, Jira, SharePoint, and content and marketing tools, suggesting capabilities in data integration, operational efficiency, and collaboration that can be cross-sold to sponsors seeking end-to-end data sciences, operational excellence, and streamlined project management in clinical research.